Loading...
XTAI
1737
Market cap223mUSD
Jul 14, Last price  
32.70TWD
1D
-0.15%
1Q
4.14%
Jan 2017
11.60%
IPO
19.04%
Name

Taiyen Biotech Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
17.60
P/S
2.02
EPS
1.86
Div Yield, %
3.67%
Shrs. gr., 5y
0.30%
Rev. gr., 5y
2.18%
Revenues
3.24b
-5.01%
1,980,143,0002,152,877,0002,298,251,0002,296,293,0002,408,819,0002,597,177,0002,761,204,0002,755,185,0002,757,075,0003,001,462,0002,906,615,0003,130,347,0004,095,651,0003,613,607,0003,408,811,0003,238,152,000
Net income
372m
+23.68%
209,768,000181,410,000194,067,00078,105,000125,954,000214,469,000268,930,000351,967,000353,694,000452,741,000345,503,000365,085,000393,227,000426,704,000300,386,000371,524,000
CFO
660m
+45.23%
358,023,000300,887,000246,089,000154,460,000203,212,000371,061,000383,926,000568,064,000607,866,000449,834,000330,807,000339,356,000600,076,000580,689,000454,539,000660,116,000
Dividend
Aug 20, 20241.2 TWD/sh
Earnings
Jul 28, 2025

Profile

Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. Its products portfolio includes various salt and seawater chemical products; bath salt, bath salt milk, salt soap, algae soap, and shampoo; beverage and drinking water; toothpaste, salt mouthwash, and contact lenses maintenance liquid; salt for washing vegetables, fruits, and other products; and food and food additives. The company also manufactures pharmaceuticals, including cosmetics and environmental medicines. In addition, it imports and exports daily necessities and cosmetic products. Further, the company is involved in the supply, introduction, and management consulting of industrial salt technology. Taiyen Biotech Co., Ltd. was founded in 1952 and is based in Tainan, Taiwan.
URL
https://www.tybio.com.tw/
IPO date
Nov 18, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,238,152
-5.01%
3,408,811
-5.67%
3,613,607
-11.77%
Cost of revenue
2,807,343
3,061,578
3,168,557
Unusual Expense (Income)
NOPBT
430,809
347,233
445,050
NOPBT Margin
13.30%
10.19%
12.32%
Operating Taxes
115,580
111,820
103,071
Tax Rate
26.83%
32.20%
23.16%
NOPAT
315,229
235,413
341,979
Net income
371,524
23.68%
300,386
-29.60%
426,704
8.51%
Dividends
(240,000)
(300,000)
(300,000)
Dividend yield
3.63%
4.38%
4.61%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
280,053
219,592
170,840
Long-term debt
66,184
129,950
135,385
Deferred revenue
297,721
307,188
320,053
Other long-term liabilities
179,756
230,713
171,907
Net debt
(1,246,044)
(2,758,062)
(1,256,833)
Cash flow
Cash from operating activities
660,116
454,539
580,689
CAPEX
(307,610)
(341,650)
(246,603)
Cash from investing activities
(287,763)
(339,300)
(229,635)
Cash from financing activities
(266,525)
(199,218)
(547,979)
FCF
421,545
121,071
164,282
Balance
Cash
1,937,932
1,839,582
1,887,221
Long term investments
(345,651)
1,268,022
(324,163)
Excess cash
1,430,373
2,937,163
1,382,378
Stockholders' equity
2,703,852
4,050,437
4,160,326
Invested Capital
6,026,262
4,466,765
5,997,677
ROIC
6.01%
4.50%
5.74%
ROCE
5.75%
4.67%
6.00%
EV
Common stock shares outstanding
203,536
200,477
200,644
Price
32.45
-5.12%
34.20
5.39%
32.45
-2.26%
Market cap
6,604,729
-3.67%
6,856,313
5.31%
6,510,898
-2.22%
EV
5,362,213
4,155,851
5,394,755
EBITDA
649,402
545,292
639,998
EV/EBITDA
8.26
7.62
8.43
Interest
6,338
3,349
4,523
Interest/NOPBT
1.47%
0.96%
1.02%